Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of immune-supporting non-vitamin A benefits. These benefits have wide, global utility, including serving as an alternative to antibiotics in livestock feeds, as well as for food- production conditions where antibiotics cannot be used, and supporting good health in companion animals.

Our Mission

Our mission is to deliver quality products to our customers by adopting best practices and continually monitoring industry trends to match and exceed the future expectations of the markets.


Our goal is to offer scientifically proven solutions that can truly benefit humans, food and companion animals by taking advantage of natural physiological mechanisms for maintaining optimal health.

Avivagen Inc. operates in the multi-billion dollar animal and human health markets. The company’s goal is to commercialize a range of product applications from its technology platform with:

  • Secured licensing agreements
  • Collaborations and alliances with selected industry partners
  • The successful launch of pet products in the US, Canada and internationally
  • The strengthening of an already sound IP portfolio

Avivagen’s technology supports the natural systems that exist within the body to maintain optimal health and function, particularly by supporting immune function. Avivagen’s OxC-beta™ technology is based on its β-carotene-oxygen copolymer discovery.

Avivagen’s target markets are

  • Supporting Livestock Health & Productivity Enhancement
  • Enhancement of Pet Wellness
  • Human Health and Wellness

The OxC-beta™ platform addresses all three target markets.

Avivagen is a publicly listed biotechnology company trading on the TSX Venture Exchange under the ticker “VIV” and the OTCQB under the symbol “VIVXF”. The company has two R&D operations located in the Industrial Partnership Facilities at the National Research Council of Canada (NRC) in Ottawa (Chemistry), and in Charlottetown, Prince Edward Island (Nutriscience). Avivagen is headquartered in Ottawa, Canada and was established August 4th, 2005.

The Avivagen Team

  • Kym Anthony


    • Extensive experience in capital markets, agriculture and life sciences
    • Current Chair, Hybrid Partners and Executive Chair, Top Meadow Investments, Inc.
    • Previously Chair of Prometic Life Sciences Inc.
  • David Hankinson

    Vice Chairman of the Board

    • Former President and CEO of Solvay Pharma Inc.
    • Co-founded a pharmaceutical distribution operation as VP of Kingswood Canada Inc.
    • Prior work experience includes 15 years in various positions at Eli Lilly.
  • Tracy Gillett, BVSc

    Director, Companion Animal

    • Bachelor of Veterinary Science from the University of Queensland, Australia.
    • 10 years experience in companion and mixed animal practice in Australia and the UK
    • Worked for Bayer Animal Health, New Zealand prior to position with Avivagen. Gained valuable experience within one of the world’s largest multinational pharmaceutical companies.
  • Graham Burton, PhD

    Chief Scientific Officer

    • Co-founded Avivagen after 19 years of biomedical research at the National Research Council of Canada. (NRC)
    • At NRC developed the foundation for Avivagen’s oxidized β-carotene technology.
    • Internationally known as a leading scientist in vitamin E research.
  • James Nickerson, PhD

    Executive VP Business Development & Product Innovation

    • Joined Avivagen as a senior research biologist and has held various research and management positions during his career with the company.
    • Established Avivagen’s biological research facility and has directed the company’s biology research program for the past 10 years.
    • Holds graduate degrees and postdoctoral research experience in the fields of molecular biology and physiology.
  • ChrisBoland

    Chris Boland , CPA, CA, CMA, B.COMM.

    Chief Financial Officer

    • Completed the CICA Advanced Taxation and Advanced IFRS studies.
    • 25 years’ experience in corporate finance, IFRS, SOX, ERM, public reporting, anti-fraud measures and corporate governance.
    • Serves on the Board of Directors of CMAO, and previously on the Board of ICAO, CPA of Ontario.
  • Drew Basek

    Director, Investor Relations

    • B.A. Honours (Economics) from Queen’s University, followed six years later with an MBA (Finance & Marketing) from The Rotman School of Management (University of Toronto).
    • 25 years in the investment industry including working on Fixed Income and Foreign Exchange desks (Merrill Lynch Canada, Bankers Trust Canada).
    • 15 years as an Institutional Equity Salesperson (Deutsche Bank, Levesque Beaubien) including the position of Head of Institutional Sales at Dundee Securities.